Colchicine

Global Antihypertensive Drugs Market 2019-2023| Evolving Opportunities with AstraZeneca and Johnson & Johnson Services, Inc. | Technavio

Retrieved on: 
화요일, 11월 19, 2019
Health, Pharmaceutical, Health, Chemistry, RTT, Pharmacy, Pharmaceuticals policy, Alkaloids, Colchicine, Ketones, Pharmaceutical industry, Medication, AstraZeneca

The market is driven by the availability of a wide range of antihypertensive drugs.

Key Points: 
  • The market is driven by the availability of a wide range of antihypertensive drugs.
  • In addition, the development of modified-release formulations is anticipated to further boost the growth of the antihypertensive drugs market.
  • Major Five Antihypertensive Drugs Market Companies:
    AstraZeneca is headquartered in the UK and operates under the business segment: Biopharmaceuticals.
  • Request a free sample report
    Related Reports on Health Care are:
    Pericarditis Drugs Market Global Pericarditis Drugs Market by product (NSAIDs, colchicine, and others) and geography (Asia, Europe, North America, and ROW).

Colchicine significantly reduces the risk of first and total ischemic cardiovascular events by 23% and 34% respectively in addition to standard of care in patients with a recent myocardial infarction (MI)

Retrieved on: 
토요일, 11월 16, 2019
RTT, Organic compounds, Chemical compounds, Chemistry, Colchicine, Myocardial infarction, Cardiovascular disease

In this study, patients receiving colchicine 0.5mg daily had a significantly lower rate of first and total (first and recurrent) ischemic cardiovascular events than those on placebo1.

Key Points: 
  • In this study, patients receiving colchicine 0.5mg daily had a significantly lower rate of first and total (first and recurrent) ischemic cardiovascular events than those on placebo1.
  • 34% reduction in the risk of total (first and recurrent) events of the primary efficacy endpoint (RR, 0.66, 95% CI, 0.51-0.86, p=0.002) 1.
  • These data underscore the potential of colchicine as an efficient and critically needed therapy for reducing inflammation post-myocardial infarction to improve patient cardiovascular outcomes.
  • Colchicine was generally well-tolerated with nausea in 1.8% and 1.0% (p=0.02) of patients in the colchicine and placebo groups respectively1.

ROMEG Therapeutics Secures Two Additional U.S. Patents

Retrieved on: 
화요일, 8월 20, 2019
Biotechnology, FDA, Health, Pharmaceutical, Health, Articles, Pharmacy, Alkaloids, Colchicine, Ketones, RTT, Pharmaceutical industry in China, Medication, Food and Drug Administration, Pharmaceutical industry

Specifically, the two patents will broaden the composition claims of the colchicine oral solutions and cover methods to potentially enable additional indications.

Key Points: 
  • Specifically, the two patents will broaden the composition claims of the colchicine oral solutions and cover methods to potentially enable additional indications.
  • GLOPERBA, approved by the FDA earlier this year, was recently licensed to Avion Pharmaceuticals, LLC of Alpharetta, Ga., for exclusive commercialization within the United States.
  • ROMEG Therapeutics, LLC, is a privately held specialty pharmaceutical company based in Woburn, Mass.
  • The company is focused on developing a broad intellectual property portfolio to offer novel therapies to provide patients and physicians better treatment options.

Avion Pharmaceuticals, LLC, and ROMEG Therapeutics, LLC, finalize partnership agreement to license and commercialize Gloperba, a prophylactic treatment of gout in adults

Retrieved on: 
화요일, 7월 16, 2019
Organic compounds, Chemical compounds, Medicine, Acetamides, Alkaloids, Colchicine, Ketones, RTT, Tablet, Indometacin, Gout, Dysphagia

Gloperba is a new liquid oral dosage form of colchicine indicated for the prophylaxis of gout flares in adults.

Key Points: 
  • Gloperba is a new liquid oral dosage form of colchicine indicated for the prophylaxis of gout flares in adults.
  • Gloperba can fill that important void in treatment where patients may have difficulty swallowing pills.
  • "This partnership provides optimal distribution of and access to this new liquid oral dosage form of colchicine to deliver this important therapy to patients and prescribers.
  • ROMEG's aptitude for drug development has resulted in a unique opportunity for this patient segment suffering from gout.

Worldwide Pericarditis Drugs Market Outlook 2019-2023 - The Side Effects Associated with Pericarditis Drugs is Hindering Growth (4% CAGR) - ResearchAndMarkets.com

Retrieved on: 
금요일, 6월 28, 2019
Health, Pharmaceutical, Chemical compounds, Organic compounds, Medical specialties, RTT, Hepatotoxins, Nonsteroidal anti-inflammatory drugs, Pericarditis, Colchicine, Indometacin

The pericarditis drugs market will register a CAGR of over 4% by 2023.

Key Points: 
  • The pericarditis drugs market will register a CAGR of over 4% by 2023.
  • Thus, the rising prevalence of pericarditis increases the demand for pericarditis drugs, which drives market growth.
  • Hence, the rising cases of PPS increase the demand for pericarditis drugs, which contributes to market growth.
  • The global pericarditis drugs market is predominantly led by NSAIDs and colchicine, owing to their therapeutic benefits.

ROMEG Therapeutics Receives FDA Approval of GLOPERBA® (colchicine) for Prophylaxis of Adult Gout Flares

Retrieved on: 
화요일, 2월 26, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, FDA, Organic compounds, Chemical compounds, Chemistry, Acetamides, Alkaloids, Colchicine, Ketones, Gout

ROMEG Therapeutics , an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the U.S. Food and Drug Administration (FDA) approved GLOPERBA (colchicine) Oral Solution, 0.6 mg/5 mL for prophylaxis of gout flares in adults.

Key Points: 
  • ROMEG Therapeutics , an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the U.S. Food and Drug Administration (FDA) approved GLOPERBA (colchicine) Oral Solution, 0.6 mg/5 mL for prophylaxis of gout flares in adults.
  • GLOPERBA is the first liquid formulation of colchicine approved by the FDA for the prophylaxis of gout flares.
  • GLOPERBA represents an important advancement for patients who are experiencing the recurring, painful effects of gout, said Naomi Vishnupad, Ph.D., Chief Scientific Officer of ROMEG Therapeutics.
  • ROMEG Therapeutics, LLC, a privately held specialty pharmaceutical company based in Woburn, Mass., was founded by Indu Muni and Gita Muni in 2015.

Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States

Retrieved on: 
월요일, 7월 2, 2018
Chemistry, Medicine, Organic chemistry, Acetamides, Alkaloids, Colchicine, Ketones, RTT, Gout, Tablet

Endo's subsidiary, Endo Ventures Limited, entered into an exclusive U.S. supply and distribution agreement with Takeda Pharmaceuticals U.S.A., allowing Par to launch and distribute an authorized generic of the product.

Key Points: 
  • Endo's subsidiary, Endo Ventures Limited, entered into an exclusive U.S. supply and distribution agreement with Takeda Pharmaceuticals U.S.A., allowing Par to launch and distribute an authorized generic of the product.
  • Taking certain medicines with COLCRYS can cause your level of COLCRYS to be too high, even at recommended doses, especially if you have kidney or liver problems.
  • You have a higher chance for muscle problems if you are elderly, are taking certain other medicines with COLCRYS, or have kidney problems.
  • COLCRYS (colchicine, USP) 0.6 mg tablet is a prescription medicine used in adults to prevent and treat gout flares.

Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States

Retrieved on: 
월요일, 7월 2, 2018
Chemistry, Medicine, Organic chemistry, Acetamides, Alkaloids, Colchicine, Ketones, RTT, Gout, Tablet

Endo's subsidiary, Endo Ventures Limited, entered into an exclusive U.S. supply and distribution agreement with Takeda Pharmaceuticals U.S.A., allowing Par to launch and distribute an authorized generic of the product.

Key Points: 
  • Endo's subsidiary, Endo Ventures Limited, entered into an exclusive U.S. supply and distribution agreement with Takeda Pharmaceuticals U.S.A., allowing Par to launch and distribute an authorized generic of the product.
  • Taking certain medicines with COLCRYS can cause your level of COLCRYS to be too high, even at recommended doses, especially if you have kidney or liver problems.
  • You have a higher chance for muscle problems if you are elderly, are taking certain other medicines with COLCRYS, or have kidney problems.
  • COLCRYS (colchicine, USP) 0.6 mg tablet is a prescription medicine used in adults to prevent and treat gout flares.